In our exclusive interview, Jay Hatfield (Founder, CEO, and Portfolio Manager at InfraCap) outlines a disciplined approach to small-cap investing built around profitability, valuation, and income generation and discusses the opportunity set for small caps as macro conditions evolve.Jay breaks down the portfolio construction behind InfraCap Small Cap Income Fund (NYSE: SCAP), designed to target 7%+ yield by focusing on profitable, dividend-paying companies, selective preferred exposure, and measured options activity.Key topics we covered:• SCAP’s mandate and portfolio filters: why profitability is non-negotiable in small caps• Income-first small caps: combining dividend payers with preferreds and selective call writing• Risk management lessons: avoiding the “blowups” that drive long-term underperformance• Valuation discipline: using PEG / PEGY (growth + yield) to prevent overpaying• Small-cap setup: why undercoverage and depressed relative valuations can create opportunity• Macro watchlist: why core PCE inflation is the key input for Fed policy and small-cap momentumSmall caps remain an under-researched segment of the market. Jay's process emphasizes repeatable underwriting, downside control, and income as a contributor to total return, particularly in environments where rate expectations and inflation data can shift sentiment quickly.#Investing #SmallCaps #IncomeInvesting #Dividends #PreferredStocks #Macro #FederalReserve #SCAPThis post contains sponsored content. This content is for informational purposes only and is not intended to be investment advice. The opinions RedChip expresses are solely their own and are not the opinions of Infrastructure Capital Advisors, LLC, nor its affiliates. The opinions expressed are for information purposes only and do not constitute an offer to buy or sell securities, options, or cryptocurrency. Please conduct your own research and consult your own tax attorney or financial advisor before making an investment decision. The information in this video and the corresponding websites is neither an offer nor a recommendation to buy or sell any security, options on equities, or cryptocurrency. Past performance is not necessarily indicative of future results. No trading strategy is risk-free. Trading and investing involve substantial risk, and you may lose the entire amount of your principal investment or more. You should trade or invest only “risk capital” – money you can afford to lose. ICA has not been involved in the preparation of the content supplied at these websites, and does not endorse these websites, their sponsors, or any of the policies, products, activities, or services offered on the sites. The content is provided, “as is”, without representation or warranty, express or implied, as to their accuracy, completeness, or timeliness of such content, all of which ICA disclaims. This is not financial advice, and returns are not guaranteed. Do your own due diligence before investing.

Watch our replay of Enlivex’s FY25 Financial Results Webcast to hear management discuss the company’s outlook, financial performance, and its differentiated dual strategy combining quality longevity therapeutics with a prediction markets treasury model.Key FY2025 Highlights:• Net income of $1.23 billion• Diluted EPS of $25.48• Total treasury and treasury-related derivative assets of $2.31 billion• Shareholders’ equity of $1.93 billion• $30.0 million in cash, cash equivalents, and short-term investments in digital assetsEnlivex is positioning itself as a public market vehicle with exposure to two high-interest themes:• Quality longevity therapeutics, led by Allocetra™ and its focus on inflammatory conditions associated with aging• Prediction markets infrastructure, through treasury exposure tied to the RAIN protocol👉 Enlivex is a client of RedChip. Visit https://www.ENLVinfo.com to learn more and sign up for news alerts.#ENLV #Enlivex #Nasdaq #SmallCapStocks #MicroCapStocks #BiotechStocks #GrowthStocks #StockMarket #InvestorUpdate #Earnings #HealthcareStocks #Longevity #DigitalAssets

Enlivex (Nasdaq: ENLV) CEO Oren Hershkovitz breaks down the company’s two-pillar strategy designed to build shareholder value through both biotech execution and balance sheet strategy.Pillar 1: Clinical Development (AllocetraTM)Enlivex is advancing its immunotherapy platform with a focus on knee osteoarthritis, a large and growing market with limited effective treatment options. In the interview, management discusses durable, statistically significant results in an older, underserved OA population and the roadmap toward later-stage clinical development.Pillar 2: Digital Asset Treasury Management (Prediction Markets via RAIN)Enlivex is also pursuing a treasury strategy centered on prediction markets, with exposure to the RAIN token. The CEO outlines why the company believes event-driven markets are scaling rapidly, why being an early mover could matter, and how treasury gains and yield could be used to both expand the treasury position and support accelerated clinical development.How the two pillars connectThe core thesis is a dual-engine approach: potential value creation from late-stage clinical catalysts on one side, paired with a treasury strategy intended to generate incremental upside and potentially support funding needs on the other, aiming to reduce reliance on dilution while maintaining momentum in the pipeline.Topics covered:• Why Enlivex believes its two pillars can work together to drive shareholder value• Knee osteoarthritis focus and why age-related patients matter medically and commercially• The RAIN treasury strategy, optionality, and what management sees as the long-term upside• What investors should watch next and the timeline discussed in the interview👉 Enlivex is a client of RedChip. To learn more about ENLV and to read our full disclosure, visit: https://www.ENLVinfo.com#ENLV #SmallCapStocks #BiotechStocks #NASDAQ #Osteoarthritis #ClinicalTrials #InvestorInterview #MicroCapStocks

Off The Hook (NYSE American: OTH) CEO Brian John joins us for an exclusive interview to break down what makes OTH different from a traditional boat dealer and why management believes the company is entering a major growth phase.In our conversation, Brian explains how Off The Hook’s AI-powered platform helps price and move used boats with speed and accuracy, positioning the company as a high-velocity marine liquidity platform in the fragmented U.S. used boat market. The company says it generated approximately $82.6 million in revenue in the first nine months of 2025, delivered about $99 million in FY2024 revenue, and has guided to $140 million to $145 million in FY2026 revenue, excluding the expected impact of the Apex acquisition and post-IPO floorplan expansion.Off The Hook is pitching a differentiated model built around used boat liquidity, vertical integration, and margin capture across sourcing, brokerage, auctions, financing, warranty, and insurance.👉 Off The Hook is a client of RedChip. To learn more about OTH and to read our full disclosure, visit: https://www.redchip.com/stocks/OTH#OTH #OffTheHook #NYSEAmerican #SmallCapStocks #StockMarket #GrowthStocks #InvestorInterview #BrianJohn #BoatingIndustry #AIStocks

What makes Comprehensive Healthcare Systems (OTCQB: CMHSF | TSXV: CHS) a story investors should be watching right now?In our exclusive interview, Chris Cosgrove, President & CEO of Comprehensive Healthcare Systems, breaks down how the company is building a scalable healthcare SaaS platform designed to automate complex benefits administration for unions, self-insured employers, third-party administrators, and government clients.CHS' proprietary Novus 360 platform is built to replace fragmented legacy systems with an integrated solution for eligibility, claims processing, pension administration, compliance, and member engagement. The company is targeting a large U.S. healthcare benefits administration software market estimated at $4B to $6B annually, while already supporting more than 1 million members and processing over $1.8B in healthcare claims.In our interview, Chris discusses:• Why CHS’s position in the government-mandated Taft-Hartley market creates a potential competitive moat• How Novus 360 can automate up to 85% of claims adjudication and improve workflow efficiency• Why the company believes it can scale through both organic growth and acquisitions• Annualized recurring revenue targets of about $10M by year-end 2026, with expected gross margins of 65% to 70% and EBITDA margins of 10% to 15%• The path from approximately US$25M in signed contracts today toward a US$100M contract target by 2028For investors looking at underfollowed healthcare technology and small-cap SaaS opportunities, this interview offers insight into CHS’s strategy, operating leverage potential, and growth roadmap.👉 Comprehensive Healthcare Systems is a client of RedChip. To learn more about CMHSF and to read our full disclosure, visit: https://www.redchip.com/stocks/CMHSF#CMHSF #CHS #OTCQB #TSXV #SmallCapStocks #HealthcareStocks #SaaSStocks #GrowthStocks #StockMarket #Investing #HealthcareTechnology

​  @themetalscompany  (Nasdaq: TMC) is a developer of lower-impact critical metals from seafloor polymetallic nodules, on a dual mission: (1) supply metals for energy, defense, manufacturing and infrastructure with net positive impacts compared to conventional production routes and (2) trace, recover and recycle the metals we supply to help create a metal commons that can be used in perpetuity. The Company has conducted more than a decade of research into the environmental and social impacts of offshore nodule collection and onshore processing. More information is available at www.metals.co.Visit Metals.co to learn more.

BioVie (Nasdaq: BIVI) President and CEO Cuong Do joins us for an exclusive investor interview discussing BioVie’s late-clinical-stage pipeline and upcoming milestones across neurodegeneration and liver disease.In our conversation, Cuong outlines why BioVie is targeting TNFα-mediated inflammation and insulin resistance with bezisterim (formerly NE3107), plus the company’s second program, BIV201, for refractory ascites, a high-mortality complication of liver cirrhosis with no FDA-approved drug therapies today.BioVie is positioning for multiple catalysts across a differentiated clinical-stage portfolio targeting large unmet needs in neurodegeneration and liver disease, supported by an experienced leadership team.Watch the full interview for management’s full roadmap, trial design insights, and how the company is thinking about value creation over the next 12 months.👉 BioVie is a client of RedChip. To learn more about BIVI and to read our full disclosure, visit: https://www.BIVIinfo.com#BIVI #BioVie #BiotechStocks #SmallCapStocks #Investing #Parkinsons #LongCOVID #Alzheimers #ClinicalTrials #HealthcareInvesting

Lithium iron phosphate (LFP) batteries now power the majority of global battery production, but supply chains remain heavily concentrated in Asia. In our exclusive interview, First Phosphate (OTCQX: FRSPF | CSE: PHOS | FSE: KD0) CEO John Passalacqua explains how the company is working to onshore a full North American LFP supply chain, starting with high-purity igneous phosphate in Quebec and progressing downstream toward battery materials.Phosphate is a critical, heavy-by-mass input in LFP cathodes, so securing a North American supply becomes more important as demand grows across energy storage, data centers, and AI infrastructure. First Phosphate highlights its Quebec igneous phosphate as a potential advantage because higher-purity, low-contaminant feedstock can translate into more efficient production of battery-grade purified phosphoric acid versus many sedimentary sources.👉 First Phosphate is a client of RedChip. To learn more about FRSPF and to read our full disclosure, visit: https://www.FRSPFinfo.com#FRSPF #PHOS #BatteryMetals #LFP #EnergyStorage #CriticalMinerals #SmallCapStocks #MicroCapInvesting

In our investor-focused interview, Mark White, CEO of Nexalin Technology (Nasdaq: NXL), breaks down how the company is building a non-invasive neurostimulation platform aimed at major unmet needs across brain health, including depression, insomnia, PTSD/TBI, and Alzheimer’s/dementia.Nexalin’s mission is to lead what it calls the “brain health movement” with treatment designed to be safe, effective, and drug-free, supported by a growing body of peer-reviewed research and a roadmap centered on Mood, Military, and Memory.Nexalin’s edge is its frequency-based approach designed to emulate natural brain activity through Deep Intracranial Frequency Stimulation (DIFS™). Clinical validation includes peer-reviewed results published in Radiology showing improved cognition and stronger brain network connectivity in mild Alzheimer’s disease. Additional peer-reviewed findings point to broader potential, including blood pressure reduction in depression (Journal of Affective Disorders) and improved attention with normalized brain activity in ADHD (Molecular Psychiatry).👉 Nexalin Technology is a client of RedChip. To learn more about NXL and to read our full disclosure, visit: https://www.NXLinfo.com#NXL #Nexalin #Nasdaq #SmallCapStocks #MicroCapStocks #StockMarket #GrowthStocks #BiotechStocks #MedTech #DigitalHealth #MedicalDevices #Neurostimulation

Darren Wang, Founder, Chairman, and CEO of OBOOK Holdings (Nasdaq: OWLS), joins us to discuss how OwlTing is building a compliance-first stablecoin and fiat payment infrastructure for global commerce, as well as what investors should watch in 2026.In our interview, Darren explains why stablecoins are moving beyond speculation into real-world settlement, how OwlPay supports enterprise-scale integrations, and how OWLS is positioning for utilization-driven growth as global payment rails modernize.OWLS is targeting a massive and growing global payments market, with company materials citing global payments revenue above $2.5T in 2024 and projected to exceed $3.0T by 2029, while stablecoins and cross-border settlement are among the fastest-growing segments.👉 OBOOK Holdings is a client of RedChip. To learn more about OWLS and to read our full disclosure, visit: https://www.OWLSinfo.com #Fintech #Stablecoins #Payments #Nasdaq #TechInvesting #OWLS